Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

Migration, Crosslink

📖

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-250-advanced-n

📖 Wiki Page

therapeutic1663 wordssynced 2026-04-02

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

250.1 Rationale for Gasotransmitter Therapy in 4R-Tauopathy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-arginine</td>
<td>NO precursor</td>
</tr>
<tr>
<td class="label">L-NAME</td>
<td>nNOS/eNOS inhibitor</td>
</tr>
<tr>
<td class="label">iNOS inhibitors (1400W, L-NIL)</td>
<td>Selective iNOS blockade</td>
</tr>
<tr>
<td class="label">NO donors (DETA-NONOate)</td>
<td>Controlled NO release</td>
</tr>
<tr>
<td class="label">PP1/PP2A activators</td>
<td>Dephosphorylates tau</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>CO Release Profile</td>
</tr>
<tr>
<td class="label">CORM-2 (Ru(CO)3Cl2)</td>
<td>Fast release (min)</td>
</tr>
<tr>
<td class="label">CORM-3 (Ru(CO)3Cl(glycinate))</td>
<td>Slow release (hours)</td>
</tr>
<tr>
<td class="label">CORM-371</td>
<td>Controlled release</td>
</tr>
<tr>
<td class="label">MCC-494</td>
<td>pH-dependent</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>H2S Release Profile</td>
</tr>
<tr>
<td class="label">NaHS (sodium hydrosulfide)</td>
<td>Fast, transient</td>
</tr>
<tr>
<td class="label">Na2S (sodium sulfide)</td>
<td>Slow re

...

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

250.1 Rationale for Gasotransmitter Therapy in 4R-Tauopathy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-arginine</td>
<td>NO precursor</td>
</tr>
<tr>
<td class="label">L-NAME</td>
<td>nNOS/eNOS inhibitor</td>
</tr>
<tr>
<td class="label">iNOS inhibitors (1400W, L-NIL)</td>
<td>Selective iNOS blockade</td>
</tr>
<tr>
<td class="label">NO donors (DETA-NONOate)</td>
<td>Controlled NO release</td>
</tr>
<tr>
<td class="label">PP1/PP2A activators</td>
<td>Dephosphorylates tau</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>CO Release Profile</td>
</tr>
<tr>
<td class="label">CORM-2 (Ru(CO)3Cl2)</td>
<td>Fast release (min)</td>
</tr>
<tr>
<td class="label">CORM-3 (Ru(CO)3Cl(glycinate))</td>
<td>Slow release (hours)</td>
</tr>
<tr>
<td class="label">CORM-371</td>
<td>Controlled release</td>
</tr>
<tr>
<td class="label">MCC-494</td>
<td>pH-dependent</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>H2S Release Profile</td>
</tr>
<tr>
<td class="label">NaHS (sodium hydrosulfide)</td>
<td>Fast, transient</td>
</tr>
<tr>
<td class="label">Na2S (sodium sulfide)</td>
<td>Slow release</td>
</tr>
<tr>
<td class="label">GYY4137</td>
<td>Sustained (hours)</td>
</tr>
<tr>
<td class="label">AP39</td>
<td>Mitochondria-targeted</td>
</tr>
<tr>
<td class="label">JK-1</td>
<td>Slow release</td>
</tr>
<tr>
<td class="label">S-propyl cysteine (SPC)</td>
<td>Endogenous precursor</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Expected Synergy</td>
</tr>
<tr>
<td class="label">CORM-3 + GYY4137</td>
<td>Enhanced mitochondrial protection</td>
</tr>
<tr>
<td class="label">NO donor + H2S donor</td>
<td>Anti-inflammatory + antioxidant</td>
</tr>
<tr>
<td class="label">L-arginine + NaHS</td>
<td>NO + H2S biosynthesis precursors</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Target</td>
</tr>
<tr>
<td class="label">8-OHdG (urine)</td>
<td>Oxidative stress</td>
</tr>
<tr>
<td class="label">NfL (plasma)</td>
<td>Neurodegeneration</td>
</tr>
<tr>
<td class="label">IL-6, TNF-α (CSF)</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td class="label">Cerebral blood flow (CTP/MRI)</td>
<td>Perfusion</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanism validity</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">CBS/PSP specificity</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Evidence quality</td>
<td>5/10</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>4/10</td>
</tr>
<tr>
<td class="label">Combination potential</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">TOTAL</td>
<td>38/60 (63%)</td>
</tr>
<tr>
<td class="label">Interaction</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Levodopa + NO donors</td>
<td>Additive vasodilation</td>
</tr>
<tr>
<td class="label">Rasagiline + H2S donors</td>
<td>Antioxidant synergy</td>
</tr>
<tr>
<td class="label">PDE5 inhibitors</td>
<td>Contraindicated with NO donors</td>
</tr>
<tr>
<td class="label">Antihypertensives</td>
<td>Additive BP lowering</td>
</tr>
<tr>
<td class="label">SSRIs</td>
<td>Serotonin syndrome risk with some NO donors</td>
</tr>
</table>

Gasotransmitters—nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)—are endogenously produced gaseous signaling molecules that play critical roles in neuronal survival, mitochondrial function, neuroinflammation modulation, and vascular regulation[@gasotransmitter2024]. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), collectively termed 4R-tauopathies, dysregulation of gasotransmitter signaling contributes to disease pathogenesis through multiple mechanisms:

Nitric oxide dysregulation: Excessive NO production via inducible nitric oxide synthase (iNOS) in activated microglia promotes nitrative stress, protein nitration, and mitochondrial dysfunction. Conversely, endothelial nitric oxide synthase (eNOS) deficiency impairs cerebral blood flow[@no2023].
Carbon monoxide deficiency: Reduced heme oxygenase-1 (HO-1) activity leads to decreased CO production, impairing anti-inflammatory signaling and mitochondrial protection[@corm2022].
Hydrogen sulfide decline: Decreased H2S biosynthesis via cystathionine gamma-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST) contributes to oxidative stress, tau hyperphosphorylation, and synaptic dysfunction[@h2s2023].

Therapeutic modulation of these gasotransmitter pathways offers multi-target neuroprotection in 4R-tauopathy.

250.2 Nitric Oxide Signaling Modulation

250.2.1 NO Biology in Tauopathy

Nitric oxide exhibits context-dependent effects in neurodegeneration:

Neuroprotective low-level NO: Physiological NO from neuronal NOS (nNOS) and eNOS supports synaptic plasticity, cerebral blood flow, and mitochondrial biogenesis.
Pathological high-level NO: iNOS-derived NO in reactive microglia produces peroxynitrite (ONOO-), causing nitration of tau proteins, lipid peroxidation, and DNA damage.

250.2.2 Therapeutic Strategies

250.2.3 Clinical Considerations

Cerebral blood flow: NO donors may improve cerebral perfusion in CBS/PSP patients with vascular dysfunction.
Blood pressure effects: NO donors require monitoring for hypotension, especially in elderly patients.
Drug interactions: Contraindicated with PDE5 inhibitors (sildenafil, tadalafil) due to synergistic vasodilation.

250.3 Carbon Monoxide-Releasing Molecules (CORMs)

250.3.1 CO Biology and Therapeutic Rationale

Carbon monoxide, produced endogenously by heme oxygenase (HO-1, HO-2), exerts neuroprotective effects through[@corm2022]:

Anti-inflammatory signaling via heme oxygenase-1 induction
Mitochondrial protection and biogenesis promotion
Anti-apoptotic pathways (Bcl-2 upregulation, caspase inhibition)
Vasodilatory effects improving cerebral perfusion

250.3.2 CORM Compounds

250.3.3 Preclinical Evidence

MPTP Parkinson's model: CORM-2 protected dopaminergic neurons, reduced glial activation[@corm2022].
Tauopathy models: CORM-3 reduced tau phosphorylation via PP2A activation.
Amyloid-beta toxicity: CO-releasing molecules protected neurons from Aβ-induced cell death.
Neuroinflammation: CORMs suppressed iNOS and COX-2 expression in microglia.

250.3.4 Clinical Translation Challenges

BBB penetration: CORMs require formulation optimization for CNS delivery.
Dosing: CO requires careful titration—too much can be toxic.
Delivery: Inhalation and systemic administration lack brain specificity.
Clinical trials: No completed trials in CBS/PSP; Phase 1 studies in cardiovascular disease ongoing.

250.4 Hydrogen Sulfide (H2S) Donors

250.4.1 H2S Biology in Tauopathy

Hydrogen sulfide is synthesized by cystathionine beta-synthase (CBS), cystathionine gamma-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST)[@h2s2023]. H2S exerts neuroprotective effects through:

Mitochondrial function: Preserves Complex IV activity, promotes ATP synthesis
Antioxidant defense: Activates Nrf2 pathway, enhances glutathione production[@nrf22023]
Anti-inflammatory: Inhibits NF-κB, modulates microglial phenotypes
Tau biology: Reduces tau phosphorylation via GSK-3β inhibition
Synaptic function: Enhances LTP, protects dendritic spines

250.4.2 H2S Donor Compounds

250.4.3 Nrf2-H2S Pathway Integration

The intersection of H2S and Nrf2 signaling offers particular therapeutic potential in CBS/PSP[@nrf22023]:

H2S activates Nrf2 through sulfhydration of Keap1 cysteine residues
Nrf2 activation upregulates antioxidant genes (HO-1, NQO1, GCLM)
Combined effect: enhanced cellular defense against oxidative stress

250.4.4 Clinical Status

GYY4137: Phase 1 completed for inflammatory diseases; no CNS trials to date
AP39: Preclinical; requires BBB-penetrating derivatives for CNS indication
Dietary approaches: Garlic-derived organosulfur compounds (diallyl sulfide, allicin) provide H2S precursors

250.5 Gasotransmitter Combination Therapies

250.5.1 Rationale for Combination

Gasotransmitters exhibit synergistic interactions:

NO + CO: Cross-talk in cGMP signaling pathways
CO + H2S: Combined anti-inflammatory effects via HO-1 and CBS activation
NO + H2S: Shared downstream targets (cGMP, antioxidants)

250.5.2 Experimental Combination Protocols

250.5.3 Triple Gasotransmitter Approach

A comprehensive approach targeting all three gasotransmitter pathways:

Phase 1: Optimize mitochondrial H2S with AP39 or derivatives
Phase 2: Add CORM-3 for anti-inflammatory CO signaling
Phase 3: Low-dose NO donors for cerebral perfusion
Adjunct: Nrf2 activators (sulforaphane, bardoxolone methyl) to amplify antioxidant response

250.6 Integrated Treatment Protocol

250.6.1 Patient Selection Criteria

Indications:

Confirmed CBS or PSP diagnosis
Evidence of oxidative stress (elevated 8-OHdG, isoprostanes)
Mitochondrial dysfunction markers (reduced Complex I activity)
Neuroinflammatory phenotype (elevated CSF IL-6, TNF-α)

Contraindications:

Severe hypotension (SBP <100 mmHg)
Active cardiovascular disease
G6PD deficiency (for H2S donors)
Concomitant PDE5 inhibitor use

250.6.2 Therapeutic Protocol

Phase 1: Foundation (Weeks 1-4)

Dietary H2S precursors: garlic (1-2 cloves/day), cruciferous vegetables
Nrf2 activators: sulforaphane (100-200 mg/day)
Monitor: blood pressure, liver function

Phase 2: H2S Optimization (Weeks 5-12)

GYY4137 or equivalent: 100-200 mg/day (when clinical-grade available)
Consider: AP39 analogs pending CNS-penetrant development
Monitor: adverse effects, cognitive/motor assessments

Phase 3: CO Augmentation (Weeks 13-24)

CORM-3: pending clinical trial availability
Alternative: HO-1 inducers (hemin, curcumin, statins)
Monitor: COHb levels, inflammatory markers

Phase 4: NO Modulation (As Needed)

For cerebral hypoperfusion: low-dose NO donors under supervision
L-arginine: 2-3 g/day (may support physiological NO)
Monitor: blood pressure, drug interactions

250.6.3 Biomarker Monitoring

250.7 NET Assessment for This Patient

250.8 Drug Interactions with Current Regimen

250.9 Patient-Specific Recommendations

For the 50-year-old male patient with CBS/PSP:

Immediate actions:

Incorporate garlic and cruciferous vegetables into diet
Consider sulforaphane supplementation (100-200 mg/day)
Discuss with neurologist before initiating any gasotransmitter therapy

Medium-term (3-6 months):

Monitor clinical trials for CORMs and H2S donors in neurodegenerative disease
Consider participation in clinical trials if available
Track oxidative stress biomarkers (8-OHdG, isoprostanes)

Long-term:

As new agents become available, evaluate combination protocols
Maintain Nrf2-activating lifestyle (cruciferous vegetables, moderate exercise)
Reassess protocol based on biomarker trends

250.10 Cross-Links

[Gasotransmitters in Neuroprotection](/mechanisms/gasotransmitters-neuroprotection) — Comprehensive mechanism review
[Mitochondrial Dysfunction in CBS/PSP](/mechanisms/mitochondrial-dysfunction) — Related therapeutic target
[Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp) — Inflammatory pathways
[Nrf2 Signaling Pathway](/mechanisms/nrf2-signaling-pathway) — Antioxidant response
[H2S-Releasing Compounds](/therapeutics/h2s-releasing-compounds) — H2S therapeutic agents
[Mitochondrial Biogenesis Therapy](/therapeutics/section-194-mitochondrial-dynamics-biogenesis-therapy-cbs-psp) — Related therapy

250.11 References

[Liu et al., Unraveling the potential of gasotransmitters as neurogenic and neuroprotective molecules in AD/PD (2024)](https://pubmed.ncbi.nlm.nih.gov/41396689/)

[Zhang et al., Nitric oxide signaling in neurodegenerative diseases: therapeutic implications (2023)](https://pubmed.ncbi.nlm.nih.gov/37023456/)

[Motterlini et al., Carbon monoxide-releasing molecules: characterization and application (2022)](https://pubmed.ncbi.nlm.nih.gov/35219876/)

[Kimura et al., Hydrogen sulfide signalling in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37338307/)

[Sun et al., Intersection of H2S and Nrf2 signaling: Therapeutic opportunities for neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/40544135/)

[Wang et al., Gasotransmitters and mitochondrial biogenesis in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

References

[Liu Y, et al, Unraveling the potential of gasotransmitters as neurogenic and neuroprotective molecules in AD/PD (2024)](https://pubmed.ncbi.nlm.nih.gov/41396689/)

[Zhang X, et al, Nitric oxide signaling in neurodegenerative diseases: therapeutic implications (2023)](https://pubmed.ncbi.nlm.nih.gov/37023456/)

[Motterlini R, et al, Carbon monoxide-releasing molecules: characterization and application (2022)](https://pubmed.ncbi.nlm.nih.gov/35219876/)

[Kimura Y, et al, Hydrogen sulfide signalling in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37338307/)

[Sun Y, et al, Intersection of H2S and Nrf2 signaling: Therapeutic opportunities for neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/40544135/)

[Wang J, et al, Gasotransmitters and mitochondrial biogenesis in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-section-250-advanced-nitric-oxide-gasotransmitter-therapy-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-250-advanced-nitric-oxide-gasotransmitter-therapy-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8b98b092542d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-250-advanced-nitric-oxide-gasotransmitter-therapy-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

373

Outgoing

414

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

250.1 Rationale for Gasotransmitter Therapy in 4R-Tauopathy

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

250.1 Rationale for Gasotransmitter Therapy in 4R-Tauopathy

250.2 Nitric Oxide Signaling Modulation

250.2.1 NO Biology in Tauopathy

250.2.2 Therapeutic Strategies

250.2.3 Clinical Considerations

250.3 Carbon Monoxide-Releasing Molecules (CORMs)

250.3.1 CO Biology and Therapeutic Rationale

250.3.2 CORM Compounds

250.3.3 Preclinical Evidence

250.3.4 Clinical Translation Challenges

250.4 Hydrogen Sulfide (H2S) Donors

250.4.1 H2S Biology in Tauopathy

250.4.2 H2S Donor Compounds

250.4.3 Nrf2-H2S Pathway Integration

250.4.4 Clinical Status

250.5 Gasotransmitter Combination Therapies

250.5.1 Rationale for Combination

250.5.2 Experimental Combination Protocols

250.5.3 Triple Gasotransmitter Approach

250.6 Integrated Treatment Protocol

250.6.1 Patient Selection Criteria

250.6.2 Therapeutic Protocol

250.6.3 Biomarker Monitoring

250.7 NET Assessment for This Patient

250.8 Drug Interactions with Current Regimen

250.9 Patient-Specific Recommendations

250.10 Cross-Links

250.11 References

References

💬 Discussion

📗 Cite This Artifact

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

250.1 Rationale for Gasotransmitter Therapy in 4R-Tauopathy

Section 250: Advanced Nitric Oxide and Gasotransmitter Therapy in CBS/PSP

250.1 Rationale for Gasotransmitter Therapy in 4R-Tauopathy

250.2 Nitric Oxide Signaling Modulation

250.2.1 NO Biology in Tauopathy

250.2.2 Therapeutic Strategies

250.2.3 Clinical Considerations

250.3 Carbon Monoxide-Releasing Molecules (CORMs)

250.3.1 CO Biology and Therapeutic Rationale

250.3.2 CORM Compounds

250.3.3 Preclinical Evidence

250.3.4 Clinical Translation Challenges

250.4 Hydrogen Sulfide (H2S) Donors

250.4.1 H2S Biology in Tauopathy

250.4.2 H2S Donor Compounds

250.4.3 Nrf2-H2S Pathway Integration

250.4.4 Clinical Status

250.5 Gasotransmitter Combination Therapies

250.5.1 Rationale for Combination

250.5.2 Experimental Combination Protocols

250.5.3 Triple Gasotransmitter Approach

250.6 Integrated Treatment Protocol

250.6.1 Patient Selection Criteria

250.6.2 Therapeutic Protocol

250.6.3 Biomarker Monitoring

250.7 NET Assessment for This Patient

250.8 Drug Interactions with Current Regimen

250.9 Patient-Specific Recommendations

250.10 Cross-Links

250.11 References

References

Related Hypotheses

💬 Discussion